Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	histone deacetylase binding	MEF2A MEF2D SFPQ	3.47e-04	147	19	3	GO:0042826
GeneOntologyMolecularFunction	transcription factor binding	MED12L MEF2A MEF2D HTT KAT6A	5.63e-04	753	19	5	GO:0008134
GeneOntologyMolecularFunction	DNA-binding transcription activator activity, RNA polymerase II-specific	FOXJ2 MEF2A ALX4 MEF2D	1.70e-03	560	19	4	GO:0001228
GeneOntologyMolecularFunction	DNA-binding transcription activator activity	FOXJ2 MEF2A ALX4 MEF2D	1.76e-03	566	19	4	GO:0001216
GeneOntologyCellularComponent	chromatin	FOXJ2 MEF2A ZFHX3 ALX4 MEF2D SFPQ KAT6A	2.07e-04	1480	19	7	GO:0000785
GeneOntologyCellularComponent	cytoplasmic ribonucleoprotein granule	TNRC6B HELZ HTT	1.75e-03	269	19	3	GO:0036464
GeneOntologyCellularComponent	transcription regulator complex	MEF2A ZFHX3 ALX4 SFPQ	1.80e-03	596	19	4	GO:0005667
GeneOntologyCellularComponent	ribonucleoprotein granule	TNRC6B HELZ HTT	2.11e-03	287	19	3	GO:0035770
GeneOntologyCellularComponent	inclusion body	HTT KLHL14	2.99e-03	90	19	2	GO:0016234
HumanPheno	Downturned corners of mouth	MED12L PACS1 FBXO11 ALX4 KAT6A	3.56e-05	182	12	5	HP:0002714
HumanPheno	Upper eyelid edema	MED12L KAT6A	7.59e-05	6	12	2	HP:0012724
HumanPheno	Palpebral edema	MED12L FBXO11 KAT6A	8.71e-05	39	12	3	HP:0100540
MousePheno	abnormal circardian behavior entrainment	ZFHX3 SFPQ	1.45e-04	15	17	2	MP:0020476
MousePheno	abnormal head morphology	SLC24A4 MN1 FBXO11 ALX4 SFPQ HTT KAT6A	1.97e-04	1120	17	7	MP:0000432
MousePheno	lethality during fetal growth through weaning, incomplete penetrance	TNRC6B MN1 FBXO11 MEF2A ZFHX3 ALX4 HTT	2.02e-04	1124	17	7	MP:0011112
MousePheno	neonatal lethality	TNRC6B MN1 FBXO11 ALX4 HTT KAT6A	2.46e-04	799	17	6	MP:0002058
MousePheno	perinatal lethality, incomplete penetrance	TNRC6B MN1 FBXO11 ALX4 HTT	2.55e-04	503	17	5	MP:0011090
MousePheno	abnormal craniofacial bone morphology	SLC24A4 MN1 FBXO11 ALX4 HTT KAT6A	2.96e-04	827	17	6	MP:0002116
MousePheno	neonatal lethality, incomplete penetrance	TNRC6B MN1 FBXO11 ALX4	3.87e-04	298	17	4	MP:0011088
MousePheno	small parietal bone	MN1 ALX4	4.80e-04	27	17	2	MP:0004418
MousePheno	abnormal facial morphology	SLC24A4 MN1 FBXO11 ALX4 SFPQ KAT6A	4.97e-04	910	17	6	MP:0003743
MousePheno	craniofacial phenotype	SLC24A4 MN1 FBXO11 ALX4 SFPQ HTT KAT6A	6.93e-04	1372	17	7	MP:0005382
MousePheno	abnormal craniofacial morphology	SLC24A4 MN1 FBXO11 ALX4 SFPQ HTT KAT6A	6.93e-04	1372	17	7	MP:0000428
Domain	HJURP_C	MEF2A MEF2D	5.88e-06	4	19	2	PF12347
Domain	MADS_MEF2-like	MEF2A MEF2D	5.88e-06	4	19	2	IPR033896
Domain	HJURP_C	MEF2A MEF2D	5.88e-06	4	19	2	IPR022102
Domain	MADS	MEF2A MEF2D	1.47e-05	6	19	2	SM00432
Domain	SRF-TF	MEF2A MEF2D	1.47e-05	6	19	2	PF00319
Domain	MADS_BOX_1	MEF2A MEF2D	1.47e-05	6	19	2	PS00350
Domain	MADS_BOX_2	MEF2A MEF2D	1.47e-05	6	19	2	PS50066
Domain	TF_MADSbox	MEF2A MEF2D	2.05e-05	7	19	2	IPR002100
Domain	RRM	TNRC6B RBM33 SFPQ	1.54e-03	230	19	3	PS50102
Domain	-	TNRC6B RBM33 SFPQ	1.83e-03	244	19	3	3.30.70.330
Domain	Nucleotide-bd_a/b_plait	TNRC6B RBM33 SFPQ	2.14e-03	258	19	3	IPR012677
Domain	Homeobox_CS	ZFHX3 ALX4	1.51e-02	186	19	2	IPR017970
Domain	-	TANC2 HELZ	1.85e-02	207	19	2	1.25.40.10
Domain	RRM	RBM33 SFPQ	2.02e-02	217	19	2	SM00360
Domain	-	FOXJ2 KAT6A	2.04e-02	218	19	2	1.10.10.10
Pathway	WP_SRF_AND_MIRS_IN_SMOOTH_MUSCLE_DIFFERENTIATION_AND_PROLIFERATION	MEF2A MEF2D	1.19e-04	18	13	2	M39393
Pathway	REACTOME_MYOGENESIS	MEF2A MEF2D	3.14e-04	29	13	2	M853
Pathway	REACTOME_REGULATION_OF_MECP2_EXPRESSION_AND_ACTIVITY	TNRC6B HTT	3.83e-04	32	13	2	M27900
Pathway	WP_ENERGY_METABOLISM	MEF2A MEF2D	8.65e-04	48	13	2	M39590
Pathway	WP_CELL_DIFFERENTIATION_INDEX	MEF2A MEF2D	9.38e-04	50	13	2	M39528
Pathway	WP_CELL_DIFFERENTIATION_EXPANDED_INDEX	MEF2A MEF2D	1.30e-03	59	13	2	M39723
Pathway	REACTOME_NUCLEAR_EVENTS_KINASE_AND_TRANSCRIPTION_FACTOR_ACTIVATION	MEF2A MEF2D	1.39e-03	61	13	2	M152
Pathway	REACTOME_TRANSCRIPTIONAL_REGULATION_BY_MECP2	TNRC6B HTT	1.49e-03	63	13	2	M27862
Pubmed	MEF2 negatively regulates learning-induced structural plasticity and memory formation.	MEF2A MEF2D	2.83e-07	2	19	2	22885849
Pubmed	Chromatin Environment and Cellular Context Specify Compensatory Activity of Paralogous MEF2 Transcription Factors.	MEF2A MEF2D	2.83e-07	2	19	2	31722213
Pubmed	A Late Phase of Long-Term Synaptic Depression in Cerebellar Purkinje Cells Requires Activation of MEF2.	MEF2A MEF2D	2.83e-07	2	19	2	30699340
Pubmed	MEF2 protein expression, DNA binding specificity and complex composition, and transcriptional activity in muscle and non-muscle cells.	MEF2A MEF2D	2.83e-07	2	19	2	8798771
Pubmed	Loss of myocyte enhancer factor 2 expression in osteoclasts leads to opposing skeletal phenotypes.	MEF2A MEF2D	2.83e-07	2	19	2	32512162
Pubmed	In vivo analysis of MEF2 transcription factors in synapse regulation and neuronal survival.	MEF2A MEF2D	8.48e-07	3	19	2	22496871
Pubmed	Characterization of a cardiac-specific enhancer, which directs {alpha}-cardiac actin gene transcription in the mouse adult heart.	MEF2A MEF2D	8.48e-07	3	19	2	15491989
Pubmed	Inducible knockout of Mef2a, -c, and -d from nestin-expressing stem/progenitor cells and their progeny unexpectedly uncouples neurogenesis and dendritogenesis in vivo.	MEF2A MEF2D	8.48e-07	3	19	2	26286136
Pubmed	Distinct stages of synapse elimination are induced by burst firing of CA1 neurons and differentially require MEF2A/D.	MEF2A MEF2D	8.48e-07	3	19	2	28901289
Pubmed	MEF2 transcription factors differentially contribute to retinal ganglion cell loss after optic nerve injury.	MEF2A MEF2D	8.48e-07	3	19	2	33315889
Pubmed	Experience-Dependent and Differential Regulation of Local and Long-Range Excitatory Neocortical Circuits by Postsynaptic Mef2c.	MEF2A MEF2D	8.48e-07	3	19	2	27989458
Pubmed	An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133.	MEF2A MEF2D	8.48e-07	3	19	2	18093911
Pubmed	Alternative pre-mRNA splicing governs expression of a conserved acidic transactivation domain in myocyte enhancer factor 2 factors of striated muscle and brain.	MEF2A MEF2D	8.48e-07	3	19	2	15834131
Pubmed	Regulation of cardiomyocyte Glut4 expression by ZAC1.	MEF2A MEF2D	1.70e-06	4	19	2	20363751
Pubmed	Neurotoxin-induced selective ubiquitination and regulation of MEF2A isoform in neuronal stress response.	MEF2A MEF2D	1.70e-06	4	19	2	22764880
Pubmed	Transcriptional activity of MEF2 during mouse embryogenesis monitored with a MEF2-dependent transgene.	MEF2A MEF2D	1.70e-06	4	19	2	10207130
Pubmed	MEF2 is restricted to the male gonad and regulates expression of the orphan nuclear receptor NR4A1.	MEF2A MEF2D	1.70e-06	4	19	2	24694307
Pubmed	Regional chromosomal assignments for four members of the MADS domain transcription enhancer factor 2 (MEF2) gene family to human chromosomes 15q26, 19p12, 5q14, and 1q12-q23.	MEF2A MEF2D	1.70e-06	4	19	2	8575763
Pubmed	Spine growth in the anterior cingulate cortex is necessary for the consolidation of contextual fear memory.	MEF2A MEF2D	1.70e-06	4	19	2	21531906
Pubmed	Big mitogen-activated kinase regulates multiple members of the MEF2 protein family.	MEF2A MEF2D	1.70e-06	4	19	2	10849446
Pubmed	Requirement of MEF2A, C, and D for skeletal muscle regeneration.	MEF2A MEF2D	1.70e-06	4	19	2	24591619
Pubmed	Expression of mef2 genes in the mouse central nervous system suggests a role in neuronal maturation.	MEF2A MEF2D	1.70e-06	4	19	2	7643214
Pubmed	Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis.	MEF2A MEF2D	1.70e-06	4	19	2	11904443
Pubmed	Neuronal Myocyte-Specific Enhancer Factor 2D (MEF2D) Is Required for Normal Circadian and Sleep Behavior in Mice.	MEF2A MEF2D	1.70e-06	4	19	2	31420455
Pubmed	Early expression of the different isoforms of the myocyte enhancer factor-2 (MEF2) protein in myogenic as well as non-myogenic cell lineages during mouse embryogenesis.	MEF2A MEF2D	1.70e-06	4	19	2	8817457
Pubmed	MEF2 transcription factors regulate distinct gene programs in mammalian skeletal muscle differentiation.	MEF2A MEF2D	1.70e-06	4	19	2	25416778
Pubmed	Galpha13 regulates MEF2-dependent gene transcription in endothelial cells: role in angiogenesis.	MEF2A MEF2D	2.82e-06	5	19	2	19093215
Pubmed	Calcineurin initiates skeletal muscle differentiation by activating MEF2 and MyoD.	MEF2A MEF2D	2.82e-06	5	19	2	12694204
Pubmed	Histone demethylase LSD1 is required to induce skeletal muscle differentiation by regulating myogenic factors.	MEF2A MEF2D	2.82e-06	5	19	2	20833138
Pubmed	Expression of MEF2 genes during human cardiac development.	MEF2A MEF2D	2.82e-06	5	19	2	10458488
Pubmed	Direct regulation of FNIP1 and FNIP2 by MEF2 sustains MTORC1 activation and tumor progression in pancreatic cancer.	MEF2A MEF2D	2.82e-06	5	19	2	37772772
Pubmed	Absence of MEF2 binding to the A/T-rich element in the muscle creatine kinase (MCK) enhancer correlates with lack of early expression of the MCK gene in embryonic mammalian muscle.	MEF2A MEF2D	2.82e-06	5	19	2	8993831
Pubmed	Control of the SOST bone enhancer by PTH using MEF2 transcription factors.	MEF2A MEF2D	2.82e-06	5	19	2	17696759
Pubmed	Postsynaptic FMRP bidirectionally regulates excitatory synapses as a function of developmental age and MEF2 activity.	MEF2A MEF2D	2.82e-06	5	19	2	23511190
Pubmed	Regulatory role of MEF2D in serum induction of the c-jun promoter.	MEF2A MEF2D	2.82e-06	5	19	2	7760790
Pubmed	Cooperative transcriptional activation by the neurogenic basic helix-loop-helix protein MASH1 and members of the myocyte enhancer factor-2 (MEF2) family.	MEF2A MEF2D	2.82e-06	5	19	2	8900141
Pubmed	Regulation of the MEF2 family of transcription factors by p38.	MEF2A MEF2D	2.82e-06	5	19	2	9858528
Pubmed	The MEF2B homologue differentially expressed in mouse embryonal carcinoma cells.	MEF2A MEF2D	2.82e-06	5	19	2	7646512
Pubmed	Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1.	MEF2A MEF2D	2.82e-06	5	19	2	9753748
Pubmed	MEF2 transcription factors are key regulators of sprouting angiogenesis.	MEF2A MEF2D	2.82e-06	5	19	2	27898394
Pubmed	Comparative Application of BioID and TurboID for Protein-Proximity Biotinylation.	TNRC6B RBM33 HELZ MEF2D SFPQ	3.83e-06	457	19	5	32344865
Pubmed	New roles for the de-ubiquitylating enzyme OTUD4 in an RNA-protein network and RNA granules.	TNRC6B PACS1 HELZ FBXO11 SFPQ	4.04e-06	462	19	5	31138677
Pubmed	TRIM72, a novel negative feedback regulator of myogenesis, is transcriptionally activated by the synergism of MyoD (or myogenin) and MEF2.	MEF2A MEF2D	4.24e-06	6	19	2	20399744
Pubmed	Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases.	MEF2A MEF2D	4.24e-06	6	19	2	10737771
Pubmed	Calcium regulates transcriptional repression of myocyte enhancer factor 2 by histone deacetylase 4.	MEF2A MEF2D	4.24e-06	6	19	2	10825153
Pubmed	The expression of MEF2 genes is implicated in CNS neuronal differentiation.	MEF2A MEF2D	4.24e-06	6	19	2	9013788
Pubmed	Dual roles for MEF2A and MEF2D during human macrophage terminal differentiation and c-Jun expression.	MEF2A MEF2D	4.24e-06	6	19	2	20590529
Pubmed	Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis.	MEF2A MEF2D	5.93e-06	7	19	2	8026334
Pubmed	Histone deacetylase degradation and MEF2 activation promote the formation of slow-twitch myofibers.	MEF2A MEF2D	7.90e-06	8	19	2	17786239
Pubmed	MEF2-dependent recruitment of the HAND1 transcription factor results in synergistic activation of target promoters.	MEF2A MEF2D	7.90e-06	8	19	2	16043483
Pubmed	MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis.	MEF2A MEF2D	7.90e-06	8	19	2	30205047
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	TNRC6B PACS1 MEF2A ZFHX3 ALX4 HTT KAT6A	8.32e-06	1489	19	7	28611215
Pubmed	Combinatorial cis-acting elements control tissue-specific activation of the cardiac troponin I gene in vitro and in vivo.	MEF2A MEF2D	1.02e-05	9	19	2	9738004
Pubmed	Myocyte Enhancer Factor 2c Regulates Dendritic Complexity and Connectivity of Cerebellar Purkinje Cells.	MEF2A MEF2D	1.27e-05	10	19	2	30276662
Pubmed	Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C.	MEF2A MEF2D	1.55e-05	11	19	2	9162005
Pubmed	Enhanced Functional Genomic Screening Identifies Novel Mediators of Dual Leucine Zipper Kinase-Dependent Injury Signaling in Neurons.	MEF2A MEF2D	1.86e-05	12	19	2	28641113
Pubmed	Skeletal muscle specification by myogenin and Mef2D via the SWI/SNF ATPase Brg1.	MEF2A MEF2D	1.86e-05	12	19	2	16424906
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	TANC2 PHLDA1 TNRC6B HELZ ZFHX3 KAT6A	2.04e-05	1116	19	6	31753913
Pubmed	Coordinated regulation of differentiation and proliferation of embryonic cardiomyocytes by a jumonji (Jarid2)-cyclin D1 pathway.	MEF2A MEF2D	2.20e-05	13	19	2	21447557
Pubmed	A Mef2 gene that generates a muscle-specific isoform via alternative mRNA splicing.	MEF2A MEF2D	2.56e-05	14	19	2	8114702
Pubmed	Cyclin D-cdk4 activity modulates the subnuclear localization and interaction of MEF2 with SRC-family coactivators during skeletal muscle differentiation.	MEF2A MEF2D	2.56e-05	14	19	2	12130539
Pubmed	Specific control of pancreatic endocrine β- and δ-cell mass by class IIa histone deacetylases HDAC4, HDAC5, and HDAC9.	MEF2A MEF2D	2.56e-05	14	19	2	21953612
Pubmed	Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development.	MEF2A MEF2D	2.96e-05	15	19	2	19782130
Pubmed	A genome-wide screen to identify transcription factors expressed in pelvic Ganglia of the lower urinary tract.	FOXJ2 MEF2A ZFHX3 ALX4 MEF2D	3.18e-05	709	19	5	22988430
Pubmed	MEF2C transcription factor controls chondrocyte hypertrophy and bone development.	MEF2A MEF2D	3.83e-05	17	19	2	17336904
Pubmed	MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders.	MEF2A MEF2D	3.83e-05	17	19	2	27779093
Pubmed	Overlapping Activities of Two Neuronal Splicing Factors Switch the GABA Effect from Excitatory to Inhibitory by Regulating REST.	TANC2 MEF2A MEF2D	4.52e-05	128	19	3	30995482
Pubmed	Identification of 14-3-3epsilon substrates from embryonic murine brain.	TANC2 PACS1 SFPQ	4.95e-05	132	19	3	16944949
Pubmed	Regulation of skeletal muscle sarcomere integrity and postnatal muscle function by Mef2c.	MEF2A MEF2D	5.90e-05	21	19	2	17875930
Pubmed	Transgenic mouse proteomics identifies new 14-3-3-associated proteins involved in cytoskeletal rearrangements and cell signaling.	TANC2 PACS1 SFPQ	6.82e-05	147	19	3	16959763
Pubmed	KLF13 is a genetic modifier of the Holt-Oram syndrome gene TBX5.	MEF2A MEF2D	7.10e-05	23	19	2	28164238
Pubmed	The Eyes Absent family members EYA4 and EYA1 promote PLK1 activation and successful mitosis through tyrosine dephosphorylation.	TNRC6B RBM33 SFPQ	7.53e-05	152	19	3	38360978
Pubmed	Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes.	FOXJ2 FBXO11 MEF2A ALX4 MEF2D	7.83e-05	857	19	5	25609649
Pubmed	Human transcription factor protein interaction networks.	TNRC6B RBM33 HELZ MEF2A ZFHX3 MEF2D	8.14e-05	1429	19	6	35140242
Pubmed	A census of human transcription factors: function, expression and evolution.	FOXJ2 MEF2A ZFHX3 ALX4 MEF2D	1.03e-04	908	19	5	19274049
Pubmed	A human MAP kinase interactome.	RBM33 HELZ MEF2D SFPQ	1.24e-04	486	19	4	20936779
Pubmed	RNA microarray analysis in prenatal mouse cochlea reveals novel IGF-I target genes: implication of MEF2 and FOXM1 transcription factors.	MEF2A MEF2D	1.39e-04	32	19	2	20111592
Pubmed	Genetic analysis of specific and redundant roles for p38alpha and p38beta MAPKs during mouse development.	MEF2A MEF2D	1.39e-04	32	19	2	21768366
Pubmed	Mef2d is essential for the maturation and integrity of retinal photoreceptor and bipolar cells.	MEF2A MEF2D	1.39e-04	32	19	2	25757744
Pubmed	The TRIM9/TRIM67 neuronal interactome reveals novel activators of morphogenesis.	TANC2 TNRC6B PACS1	2.19e-04	218	19	3	33378226
Pubmed	Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program.	MEF2A MEF2D	3.55e-04	51	19	2	20682687
Pubmed	A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants.	TNRC6B MN1	3.69e-04	52	19	2	22219177
Pubmed	Dynamin-1 co-associates with native mouse brain BKCa channels: proteomics analysis of synaptic protein complexes.	PACS1 ZFHX3	3.69e-04	52	19	2	20114047
Pubmed	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.	TNRC6B RBM33 HELZ	3.79e-04	263	19	3	34702444
Pubmed	Screening large numbers of expression patterns of transcription factors in late stages of the mouse thymus.	FOXJ2 ZFHX3 ALX4	3.79e-04	263	19	3	20932939
Pubmed	The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery.	FOXJ2 PHLDA1 RBM33 FBXO11 SFPQ	3.81e-04	1203	19	5	29180619
Pubmed	Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner.	RBM33 MEF2A MEF2D	4.00e-04	268	19	3	33640491
Pubmed	The RNA-binding ubiquitin ligase MKRN1 functions in ribosome-associated quality control of poly(A) translation.	TNRC6B HELZ	4.13e-04	55	19	2	31640799
Pubmed	Homologs of genes expressed in Caenorhabditis elegans GABAergic neurons are also found in the developing mouse forebrain.	ALX4 KAT6A	4.43e-04	57	19	2	21122108
Pubmed	Mapping the Ku Interactome Using Proximity-Dependent Biotin Identification in Human Cells.	RBM33 ZFHX3 SFPQ	4.69e-04	283	19	3	30585729
Pubmed	Conserved expression of ultra-conserved noncoding RNA in mammalian nervous system.	ZFHX3 SFPQ	4.91e-04	60	19	2	29055695
Interaction	EYA4 interactions	FOXJ2 TNRC6B RBM33 HELZ SFPQ	2.48e-06	243	19	5	int:EYA4
Interaction	CNOT2 interactions	TNRC6B HELZ ZFHX3 HTT	2.06e-05	178	19	4	int:CNOT2
Interaction	PPP1CA interactions	TANC2 PACS1 MEF2A MEF2D SFPQ HTT	3.07e-05	696	19	6	int:PPP1CA
Interaction	NUP35 interactions	TNRC6B RBM33 HELZ MEF2D SFPQ	3.67e-05	424	19	5	int:NUP35
Interaction	TTC23 interactions	MED12L ZFHX3 SFPQ HTT	3.78e-05	208	19	4	int:TTC23
Interaction	CNOT8 interactions	TNRC6B HELZ HTT	4.41e-05	74	19	3	int:CNOT8
Interaction	MEF2B interactions	MEF2A MEF2D	4.61e-05	11	19	2	int:MEF2B
Interaction	EIF4E2 interactions	TANC2 TNRC6B HTT KAT6A	7.27e-05	246	19	4	int:EIF4E2
Interaction	BORCS8-MEF2B interactions	MEF2A MEF2D	8.78e-05	15	19	2	int:BORCS8-MEF2B
Interaction	WRAP53 interactions	HELZ ZFHX3 MEF2D	9.02e-05	94	19	3	int:WRAP53
Interaction	CASP7 interactions	MEF2A MEF2D HTT	9.90e-05	97	19	3	int:CASP7
Interaction	CELF1 interactions	TNRC6B RBM33 HELZ SFPQ	1.34e-04	288	19	4	int:CELF1
Interaction	SNAP25 interactions	PACS1 ZFHX3 HTT	1.68e-04	116	19	3	int:SNAP25
Interaction	SMG7 interactions	TNRC6B RBM33 HELZ MEF2D	1.98e-04	319	19	4	int:SMG7
Interaction	AR interactions	MED12L RBM33 MEF2A ZFHX3 MEF2D SFPQ	2.19e-04	992	19	6	int:AR
Interaction	TOP3B interactions	TANC2 TNRC6B RBM33 HELZ HTT KAT6A KLHL14	2.50e-04	1470	19	7	int:TOP3B
Interaction	CNOT7 interactions	TNRC6B HELZ HTT	2.93e-04	140	19	3	int:CNOT7
Interaction	CNOT10 interactions	TNRC6B HELZ HTT	2.99e-04	141	19	3	int:CNOT10
Interaction	DAZL interactions	TNRC6B RBM33 HELZ	3.25e-04	145	19	3	int:DAZL
Interaction	DLX5 interactions	FOXJ2 ALX4	3.37e-04	29	19	2	int:DLX5
Interaction	LAMTOR5 interactions	MED12L SFPQ HTT	3.80e-04	153	19	3	int:LAMTOR5
Interaction	DDX39A interactions	SLC24A4 PHLDA1 RBM33 MN1 PACS1 KLHL14	4.10e-04	1114	19	6	int:DDX39A
Interaction	SOX6 interactions	RBM33 ZFHX3 MEF2D	4.10e-04	157	19	3	int:SOX6
Interaction	CZIB interactions	TNRC6B SFPQ	4.64e-04	34	19	2	int:CZIB
Interaction	MKRN1 interactions	TNRC6B HELZ SFPQ	4.74e-04	165	19	3	int:MKRN1
Interaction	PPIL4 interactions	SFPQ HTT KAT6A	4.74e-04	165	19	3	int:PPIL4
Interaction	SNX24 interactions	PACS1 FBXO11	4.92e-04	35	19	2	int:SNX24
Interaction	CTBP1 interactions	HELZ FBXO11 SFPQ HTT	4.95e-04	406	19	4	int:CTBP1
Interaction	UNK interactions	TNRC6B HELZ FBXO11 SFPQ	5.04e-04	408	19	4	int:UNK
Interaction	BCAN interactions	FBXO11 HTT	5.20e-04	36	19	2	int:BCAN
Interaction	MMADHC interactions	FBXO11 SFPQ	5.20e-04	36	19	2	int:MMADHC
Interaction	ALYREF interactions	RBM33 SFPQ HTT KAT6A	5.42e-04	416	19	4	int:ALYREF
Interaction	TLX1 interactions	ZFHX3 MEF2D KAT6A	5.63e-04	175	19	3	int:TLX1
Interaction	TEAD1 interactions	MEF2A ZFHX3 MEF2D	5.72e-04	176	19	3	int:TEAD1
Interaction	RNF43 interactions	TNRC6B RBM33 HELZ SFPQ	5.98e-04	427	19	4	int:RNF43
Interaction	FXR2 interactions	TNRC6B HELZ SFPQ KAT6A	6.14e-04	430	19	4	int:FXR2
Interaction	ALG13 interactions	TNRC6B RBM33 HELZ	6.41e-04	183	19	3	int:ALG13
GeneFamily	Myocyte enhancer factor 2 proteins\|MADS box family	MEF2A MEF2D	4.40e-06	4	16	2	649
GeneFamily	Myocyte enhancer factor 2 proteins\|MADS box family	MEF2A MEF2D	7.33e-06	5	16	2	1086
GeneFamily	RNA binding motif containing	RBM33 SFPQ	1.49e-02	213	16	2	725
Coexpression	BUSSLINGER_GASTRIC_IMMUNE_CELLS	PHLDA1 TNRC6B RBM33 PACS1 HELZ FBXO11 MEF2D KAT6A	4.65e-06	1492	19	8	M40023
Coexpression	GSE13738_RESTING_VS_BYSTANDER_ACTIVATED_CD4_TCELL_UP	TANC2 TNRC6B HELZ KAT6A	1.03e-05	194	19	4	M3321
Coexpression	GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_24H_CD4_TCELL_UP	RBM33 HELZ MEF2D KAT6A	1.05e-05	195	19	4	M4195
Coexpression	GSE19888_ADENOSINE_A3R_INH_PRETREAT_AND_ACT_BY_A3R_VS_TCELL_MEMBRANES_ACT_MAST_CELL_DN	PHLDA1 RBM33 HELZ MEF2D	1.14e-05	199	19	4	M7321
Coexpression	HOEBEKE_LYMPHOID_STEM_CELL_UP	MN1 MEF2A SFPQ	4.56e-05	97	19	3	M14698
Coexpression	THAKAR_PBMC_INACTIVATED_INFLUENZA_AGE_21_30YO_RESPONDERS_7DY_DN	FOXJ2 RBM33 MEF2A ZFHX3 MEF2D	7.15e-05	634	19	5	M40866
Coexpression	AIZARANI_LIVER_C33_STELLATE_CELLS_2	PHLDA1 ZFHX3 MEF2D	9.93e-05	126	19	3	M39132
Coexpression	GSE37605_TREG_VS_TCONV_NOD_FOXP3_FUSION_GFP_UP	SLC24A4 PHLDA1 RBM33	1.66e-04	150	19	3	M8796
Coexpression	GSE37532_VISCERAL_ADIPOSE_TISSUE_VS_LN_DERIVED_TREG_CD4_TCELL_DN	PACS1 HELZ MEF2D	1.83e-04	155	19	3	M8944
Coexpression	DESCARTES_ORGANOGENESIS_CHONDROCYTES_AND_OSTEOBLASTS	ZFHX3 ALX4	1.86e-04	28	19	2	MM3665
Coexpression	GSE13547_WT_VS_ZFX_KO_BCELL_ANTI_IGM_STIM_12H_DN	FOXJ2 PACS1 KLHL14	1.98e-04	159	19	3	M2983
Coexpression	GSE21033_3H_VS_24H_POLYIC_STIM_DC_UP	TNRC6B HELZ MEF2A	2.24e-04	166	19	3	M7722
Coexpression	SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_DN	TNRC6B SFPQ	2.59e-04	33	19	2	M1359
Coexpression	SIMBULAN_UV_RESPONSE_NORMAL_DN	PHLDA1 MN1	2.59e-04	33	19	2	M16114
Coexpression	DACOSTA_UV_RESPONSE_VIA_ERCC3_DN	MN1 HELZ MEF2A ZFHX3 KAT6A	2.91e-04	856	19	5	M4500
Coexpression	GSE1112_OT1_CD8AB_VS_HY_CD8AA_THYMOCYTE_RTOC_CULTURE_UP	TNRC6B PACS1 HTT	3.04e-04	184	19	3	M6141
Coexpression	SCHAEFFER_PROSTATE_DEVELOPMENT_AND_CANCER_BOX4_DN	TNRC6B SFPQ	3.27e-04	37	19	2	MM570
Coexpression	GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_48H_CD4_TCELL_UP	RBM33 MEF2D KAT6A	3.28e-04	189	19	3	M4199
Coexpression	GSE32034_UNTREATED_VS_ROSIGLIZATONE_TREATED_LY6C_LOW_MONOCYTE_UP	FOXJ2 HTT KLHL14	3.49e-04	193	19	3	M9056
Coexpression	GSE13485_DAY3_VS_DAY21_YF17D_VACCINE_PBMC_UP	SLC24A4 MEF2D SFPQ	3.49e-04	193	19	3	M3303
Coexpression	GSE21670_IL6_VS_TGFB_AND_IL6_TREATED_CD4_TCELL_UP	PACS1 MEF2A SFPQ	3.49e-04	193	19	3	M7464
Coexpression	GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_12H_CD4_TCELL_UP	TNRC6B MEF2D KAT6A	3.54e-04	194	19	3	M4192
Coexpression	GSE17974_CTRL_VS_ACT_IL4_AND_ANTI_IL12_4H_CD4_TCELL_UP	TNRC6B RBM33 MEF2D	3.54e-04	194	19	3	M4187
Coexpression	VEGF_A_UP.V1_UP	PHLDA1 MN1 HTT	3.60e-04	195	19	3	M2676
Coexpression	GSE17974_0H_VS_12H_IN_VITRO_ACT_CD4_TCELL_UP	RBM33 HELZ MEF2D	3.71e-04	197	19	3	M4167
Coexpression	GSE4142_NAIVE_BCELL_VS_PLASMA_CELL_UP	FOXJ2 RBM33 MEF2A	3.82e-04	199	19	3	M6381
Coexpression	GSE9960_GRAM_NEG_VS_GRAM_POS_SEPSIS_PBMC_DN	TNRC6B ZFHX3 HTT	3.82e-04	199	19	3	M7129
Coexpression	GSE19198_CTRL_VS_IL21_TREATED_TCELL_24H_DN	PACS1 ZFHX3 MEF2D	3.88e-04	200	19	3	M7231
Coexpression	GSE19923_WT_VS_HEB_AND_E2A_KO_DP_THYMOCYTE_DN	PHLDA1 ZFHX3 SFPQ	3.88e-04	200	19	3	M7269
Coexpression	GSE17301_CTRL_VS_48H_ACD3_ACD28_IFNA5_STIM_CD8_TCELL_UP	TNRC6B MEF2A ZFHX3	3.88e-04	200	19	3	M8050
Coexpression	GSE29164_CD8_TCELL_VS_CD8_TCELL_AND_IL12_TREATED_MELANOMA_DAY3_UP	RBM33 MEF2A ZFHX3	3.88e-04	200	19	3	M8491
Coexpression	GSE46606_UNSTIM_VS_CD40L_IL2_IL5_1DAY_STIMULATED_IRF4MID_SORTED_BCELL_UP	TANC2 PHLDA1 FBXO11	3.88e-04	200	19	3	M9833
Coexpression	GSE40666_WT_VS_STAT4_KO_CD8_TCELL_WITH_IFNA_STIM_90MIN_UP	FOXJ2 TNRC6B PACS1	3.88e-04	200	19	3	M9216
Coexpression	GSE21670_UNTREATED_VS_IL6_TREATED_CD4_TCELL_DN	TNRC6B PACS1 MEF2D	3.88e-04	200	19	3	M7441
Coexpression	FAN_OVARY_CL17_PUTATIVE_APOPTOTIC_SMOOTH_MUSCLE_CELL	PHLDA1 ZFHX3 SFPQ	5.90e-04	231	19	3	M41719
Coexpression	ROSS_AML_WITH_CBFB_MYH11_FUSION	MN1 MEF2A	6.46e-04	52	19	2	M5236
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN	TANC2 TNRC6B HELZ ZFHX3 HTT	9.24e-04	1102	19	5	M2369
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HGABA	TANC2 RBM33 PACS1 ZFHX3 KLHL14	9.39e-04	1106	19	5	M39071
Coexpression	TABULA_MURIS_SENIS_SUBCUTANEOUS_ADIPOSE_TISSUE_MESENCHYMAL_STEM_CELL_OF_ADIPOSE_AGEING	PHLDA1 MN1 ZFHX3	9.47e-04	272	19	3	MM3825
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN	TANC2 TNRC6B HELZ ZFHX3 HTT	1.01e-03	1124	19	5	MM1070
ToppCell	facs-Brain_Myeloid-Hippocampus\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MED12L TANC2 MEF2A ZFHX3 KAT6A	1.61e-08	195	19	5	a1478021a3ed0e779716393124ca2a7770c433b7
ToppCell	facs-Brain_Myeloid-Striatum-3m-Myeloid-nan\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MED12L MEF2A SFPQ KAT6A	1.11e-06	189	19	4	6dd4ec5ce4beb856f0d2d1654e3c4676d1d63736
ToppCell	facs-Brain_Myeloid-Striatum-3m-Myeloid-microglial_cell\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MED12L MEF2A SFPQ KAT6A	1.11e-06	189	19	4	875df61ee48baa5142ba4d2427bdec1c53e5a828
ToppCell	facs-Brain_Myeloid-Striatum-3m-Myeloid\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MED12L MEF2A SFPQ KAT6A	1.11e-06	189	19	4	3ae479ec7e00c57127cbe51a398329b10ca9848c
ToppCell	facs-Brain_Myeloid-Striatum-3m\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MED12L MEF2A SFPQ KAT6A	1.11e-06	189	19	4	97ef5215d841ff366a3e3682cd9bd04100cbfde0
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-5w-Neuronal-Intermediate\|5w / Sample Type, Dataset, Time_group, and Cell type.	TANC2 PHLDA1 TNRC6B ZFHX3	1.39e-06	200	19	4	c92e4fc0442404481fcac623d691dae6215b852d
ToppCell	10x5'-lymph-node_spleen-Myeloid_Mac-Intermediate_macrophages\|lymph-node_spleen / Manually curated celltypes from each tissue	SLC24A4 MN1 ZFHX3	4.49e-05	165	19	3	c3fa9225d2f9c9e821d4fbd2315fcc98ce1f1c55
ToppCell	IPF-Lymphoid-B\|World / Disease state, Lineage and Cell class	TNRC6B PACS1 KLHL14	5.82e-05	180	19	3	30f9398c9b784f49470847a025bac90687e997a1
ToppCell	nucseq-Immune-Lymphocytic_B-Lymphocytic_B-B\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	TNRC6B PACS1 KLHL14	5.92e-05	181	19	3	8d8cc4dae2c8bd5f4b1c159f2a52edc4c9449c86
ToppCell	human_hepatoblastoma-Tumor_cells\|World / Sample and Cell Type and Tumor Cluster (all cells)	TNRC6B RBM33 HELZ	7.05e-05	192	19	3	916fbec1c7ab7969bda711886ac88e877e30c280
ToppCell	facs-Aorta-Heart-3m\|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MEF2A ZFHX3 KAT6A	7.05e-05	192	19	3	1ccc47792edf9ee23501c8e2165d11271636b66a
ToppCell	Endothelial-Endothelial-B\|Endothelial / shred on cell class and cell subclass (v4)	PHLDA1 MEF2A ZFHX3	7.05e-05	192	19	3	f8d7bd81e031d09a557722627c2f6180811cc6ab
ToppCell	human_hepatoblastoma\|World / Sample and Cell Type and Tumor Cluster (all cells)	TNRC6B RBM33 HELZ	7.16e-05	193	19	3	e6a688bc834f845ff64dae1be64f073eec5091a1
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Mesenchymal-brain_pericyte\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MN1 ZFHX3 ALX4	7.16e-05	193	19	3	18e11d515147accef9aee26e934b358b445e18e2
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Mesenchymal\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MN1 ZFHX3 ALX4	7.16e-05	193	19	3	7766f495f2f945802ef9a5b994cd00bb64d0dfe3
ToppCell	facs-Brain_Myeloid-Hippocampus-3m-Myeloid-microglial_cell\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MED12L MEF2A KAT6A	7.16e-05	193	19	3	9c16032bc03df8760ae199e8f19fdafa4c3f1827
ToppCell	facs-Brain_Non-Myeloid-Cerebellum_-18m-Mesenchymal-Pericyte\|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MN1 ZFHX3 ALX4	7.16e-05	193	19	3	ce3e8cf30b7b4d5c7a8f3d64c21d81d2c3cab5c1
ToppCell	mild\|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class	RBM33 HELZ SFPQ	7.96e-05	200	19	3	12f1685ce8f218433068e090c9d839cd5a1910bf
ToppCell	368C-Lymphocytic-NK_cells-NK_cell_A\|NK_cells / Donor, Lineage, Cell class and subclass (all cells)	PHLDA1 FBXO11	1.37e-04	41	19	2	9f609afcf34f0b486dfe51e5f0e903fe357d3e91
ToppCell	PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_Arw_fibro_(16)\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	SLC24A4 ZFHX3	1.13e-03	118	19	2	e5202fadb3f9d91e56337ddad1666196ec748d87
ToppCell	3'_v3-bone_marrow-Lymphocytic_T_CD4-T_CD4/CD8\|bone_marrow / Manually curated celltypes from each tissue	TNRC6B KAT6A	1.19e-03	121	19	2	19333a660800b583fa27b495c1f7828e6636a257
ToppCell	TCGA-Cervix-Primary_Tumor-Cervical_Carcinoma-Cervical_Squamous_Cell_Carcinoma-4\|TCGA-Cervix / Sample_Type by Project: Shred V9	MED12L ZFHX3	1.33e-03	128	19	2	3ca9ae69fb8cb7f8acb7540aa71778bc917da4df
ToppCell	Control-Classical_Monocyte-\|Classical_Monocyte / Disease condition and Cell class	MED12L TANC2	1.37e-03	130	19	2	4433b40b099845f113993b6ecf85ec594b4b9219
ToppCell	TCGA-Brain-Recurrent_Tumor-Low_Grade_Glioma-Oligodendroglioma\|TCGA-Brain / Sample_Type by Project: Shred V9	ALX4 KLHL14	1.41e-03	132	19	2	6a6718582edfc59c63f2c8f753be81e0f4a7246b
ToppCell	LPS_only-Myeloid-Dendritic_cells-pDC\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	SLC24A4 MN1	1.48e-03	135	19	2	0afe232aa1a1e6c37a5b3183b67d7fa07e0ea791
ToppCell	primary_visual_cortex-Neuronal-GABAergic_neuron-Pvalb-Pvalb_Sema3e_Kank4\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	PHLDA1 KLHL14	1.48e-03	135	19	2	54b2aaf8d322e01a3ff6099c2422d68ecccf96b4
ToppCell	Fetal_brain-fetalBrain_Zhong_nature-GW26-Neuronal-Neurons\|GW26 / Sample Type, Dataset, Time_group, and Cell type.	PHLDA1 MN1	1.50e-03	136	19	2	b46450292e0cd549eb3bafdd3fed22f41d85bfbe
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW26-OPC_related-Oligodendrocyte/OPC\|GW26 / Sample Type, Dataset, Time_group, and Cell type.	MED12L PHLDA1	1.52e-03	137	19	2	8ce463d1d74ac0ce80b812217d6bd76a788f14d2
ToppCell	Fetal_brain-organoid_Tanaka_cellReport-GW26-OPC_related\|GW26 / Sample Type, Dataset, Time_group, and Cell type.	MED12L PHLDA1	1.52e-03	137	19	2	264d5e06c37d1a9ef7748091b67d2a5aa803096e
ToppCell	saliva-Mild-Moderate_progression_d12-25-Myeloid-Dendritic-conventional_dendritic_cell-DC_c3-LAMP3\|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k)	MED12L HTT	1.57e-03	139	19	2	bb2b020dda32ddc60ec9952de5b01acee60b5b59
ToppCell	LPS-IL1RA-Myeloid-Monocytes,_Macrophages-Erythroid\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MED12L MN1	1.68e-03	144	19	2	7c471e332f87d60f4dbed01f3e66bf39995218d0
ToppCell	Striatum-Neuronal-Excitatory-eN3(Slc17a7_Gad1Gad2)-Drd1\|Striatum / BrainAtlas - Mouse McCarroll V32	SLC24A4 KLHL14	1.72e-03	146	19	2	7b863f9bc63dc1afe015a18a70cd6ed0b71d1f09
ToppCell	Fetal_29-31_weeks-Immune-dendritic_cell-D088\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	SLC24A4 MED12L	1.94e-03	155	19	2	9f937ae48767fdcf1a944af4de0530d9c0ab441d
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Myocytic\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MED12L ZFHX3	1.97e-03	156	19	2	6365b69ede98bc866e996bc52736b00401aacf6f
ToppCell	PND07-28-samps-Mesenchymal-Mesothelial-Mesothelial\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	ALX4 KLHL14	1.97e-03	156	19	2	605d95a900e1443d3f6aae163ef2e893d3293203
ToppCell	PND07-28-samps-Mesenchymal-Mesothelial\|PND07-28-samps / Age Group, Lineage, Cell class and subclass	ALX4 KLHL14	1.97e-03	156	19	2	574f761962a7dd3308bd41fc529dd3ea1b8625f8
ToppCell	Smart-seq2-tissue-resident_(Smart-seq2)-myeloid-myeloid_macrophage-microglial_cell\|tissue-resident_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	MED12L TANC2	1.99e-03	157	19	2	d4908cafd8870c1c225817f589ea2bce116ac7ab
ToppCell	Bac-SEP-Lymphocyte-T_NK-dnT\|Bac-SEP / Disease, Lineage and Cell Type	PHLDA1 PACS1	2.07e-03	160	19	2	f5ca49801c981b903a85a64b21ece6b59fe91cbc
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-stromal_related-ICC\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ZFHX3 KLHL14	2.09e-03	161	19	2	deb10628d258fb813c293f81fb71be8e383dc82a
ToppCell	3'-GW_trimst-1.5-LargeIntestine-Mesenchymal-stromal_related\|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ZFHX3 KLHL14	2.09e-03	161	19	2	8aaca49b53a551395f4025ac4e535c7b0ce41a49
ToppCell	Children_(3_yrs)-Immune-dendritic_cell-D139\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SLC24A4 MED12L	2.09e-03	161	19	2	cd41abb7ae659d3d314281783a0aaad562b26037
ToppCell	normal-na-Lymphocytic_B-B_cell-male\|normal / PBMC cell types (v2) per disease, treatment status, and sex	MEF2A KLHL14	2.12e-03	162	19	2	ae292318d339305932457bb0e91430594f7a3dfa
ToppCell	Children_(3_yrs)-Immune-dendritic_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SLC24A4 MED12L	2.12e-03	162	19	2	86a0b9dabd150dc993bfc0f3344804de7f8e4042
ToppCell	10x5'-blood-Lymphocytic_T_CD4-T_CD4/CD8\|blood / Manually curated celltypes from each tissue	TNRC6B KAT6A	2.12e-03	162	19	2	b4535bcb3f469bc139e73f1122f4070013e5a1de
ToppCell	Healthy_Control-Lymphoid-B-\|Healthy_Control / Condition, Lineage, Cell class and cell subclass	MED12L KLHL14	2.14e-03	163	19	2	d84bd41b4494c7d5c7f88d511bfe481fb12f079d
ToppCell	Healthy_Control-Lymphoid-B\|Healthy_Control / Condition, Lineage, Cell class and cell subclass	MED12L KLHL14	2.14e-03	163	19	2	0f723ec2503afa1b3ebb0754972438ffb6e6179d
ToppCell	IIF-Other-HSPC\|IIF / Disease, Lineage and Cell Type	MED12L MN1	2.14e-03	163	19	2	1e0d38fbed38ac48478868a1480172a1a3f7c1b7
ToppCell	primary_visual_cortex-Non-neuronal-smooth_muscle_cell-SMC\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ZFHX3 ALX4	2.17e-03	164	19	2	9eed945e9b0c1ee5fc62724ac2bbbed4267b0678
ToppCell	367C-Myeloid-Monocyte-CD16+_Monocyte\|Myeloid / Donor, Lineage, Cell class and subclass (all cells)	KAT6A KLHL14	2.17e-03	164	19	2	1aff83fc73b4e41e6f0d4b04dbca153bcc7a3518
ToppCell	primary_visual_cortex-Non-neuronal-smooth_muscle_cell-SMC-SMC_Acta2\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ZFHX3 ALX4	2.17e-03	164	19	2	f510f20e37e31b486cdd0e3f597ce4ff00877c5d
ToppCell	primary_visual_cortex-Non-neuronal-smooth_muscle_cell\|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype	ZFHX3 ALX4	2.17e-03	164	19	2	5c932a462cbf81d029c8d11ec3aea3191529527b
ToppCell	Adult-Immune-dendritic_cell\|Adult / Lineage, Cell type, age group and donor	SLC24A4 MED12L	2.19e-03	165	19	2	073f52698dac1fe4edd7410865f81b30e1c7196a
ToppCell	10x5'-lymph-node_spleen-Hematopoietic_progenitors-Progenitor\|lymph-node_spleen / Manually curated celltypes from each tissue	MED12L MN1	2.19e-03	165	19	2	7b992843bd8ef92a7a76b1d681fa84efde6f5bdd
ToppCell	3'_v3-lymph-node_spleen-Hematopoietic_progenitors-Progenitor\|lymph-node_spleen / Manually curated celltypes from each tissue	MED12L MN1	2.25e-03	167	19	2	cb396f3edb9e8fdc316091e8e193dbba50e0be0c
ToppCell	5'-Adult-SmallIntestine-Epithelial-Tuft-related-Tuft\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	TANC2 ZFHX3	2.27e-03	168	19	2	8072d0496b7b730c4601009eaa69ec5366d26d73
ToppCell	Control-B_cells-Activated_B_cells\|Control / group, cell type (main and fine annotations)	TNRC6B KLHL14	2.27e-03	168	19	2	a7159a35fe37f8c241cf8d391debe271e0698105
ToppCell	droplet-Lung-21m-Hematologic-myeloid-interstitial_macrophage-interstitial_macrophage_l12\|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TANC2 ZFHX3	2.27e-03	168	19	2	aaafa7243c44e6852d92e3445335fc4a1018f416
ToppCell	BAL-Mild-Myeloid-cDC-cDC-cDC_11\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	SLC24A4 MED12L	2.30e-03	169	19	2	e3410ccb3f85811c75694e286115803911169a2f
ToppCell	normal_Pleural_Fluid-Myeloid_cells-Monocytes\|normal_Pleural_Fluid / Location, Cell class and cell subclass	SLC24A4 PHLDA1	2.30e-03	169	19	2	7b71463f0fd802b422c8d394a435901009ca200f
ToppCell	BAL-Mild-Myeloid-cDC-cDC-cDC_11\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	SLC24A4 MED12L	2.30e-03	169	19	2	a4f610d07c3ba5537f4497f523669b914f7eddc1
ToppCell	10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_pro-infl_II-B\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	MEF2A ZFHX3	2.30e-03	169	19	2	0867528101767fc65e93b3561480bf830c50368d
ToppCell	B_cell\|World / lung cells shred on cell class, cell subclass, sample id	MED12L KLHL14	2.33e-03	170	19	2	cec4090ba6a9c934d5f6f9e4aa7823f3713319b7
ToppCell	10x5'v1-week_17-19-Hematopoietic-HSC/MPP_and_pro-ELP\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	MN1 MEF2A	2.33e-03	170	19	2	a50e558d0b38100ccbdccb90647fe93e85bffd86
ToppCell	droplet-Lung-nan-18m-Myeloid-Interstitial_Macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TANC2 ZFHX3	2.35e-03	171	19	2	7ca404539344e14dcd90c746c9122f713a7db78b
ToppCell	Immune-dendritic_cell\|World / Lineage, Cell type, age group and donor	SLC24A4 MED12L	2.35e-03	171	19	2	6a9e2e2d3e1d8cc475bf9765129bc4a32da3b8ea
ToppCell	Children_(3_yrs)-Immune-dendritic_cell\|Children_(3_yrs) / Lineage, Cell type, age group and donor	SLC24A4 MED12L	2.35e-03	171	19	2	6a5ac0f56bd7b4543be103100fb735ca6bc5b8bf
ToppCell	droplet-Lung-nan-18m-Myeloid-lung_macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TANC2 ZFHX3	2.35e-03	171	19	2	ab113c8e773b0af47a87aed50e96be3ba71c3c82
ToppCell	droplet-Lung-nan-21m-Myeloid-lung_macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TANC2 ZFHX3	2.41e-03	173	19	2	1cff815536f620e32b9805666e1aa711462c2d25
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-B_cells-Cycling_B_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	MED12L KLHL14	2.41e-03	173	19	2	b7e0193fd4983cb38d1bee441f608f73ee8743b9
ToppCell	droplet-Lung-nan-21m-Myeloid-Interstitial_Macrophage\|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation	TANC2 ZFHX3	2.41e-03	173	19	2	31ea04e65876c42b90245d280f0b6439bfffbace
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell-\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ZFHX3 MEF2D	2.41e-03	173	19	2	fc2602b2ce051cd4c33957d7e3d041ff8a529883
ToppCell	kidney_cells-Adult_normal_reference-Mesenchymal-Myocytic_interstitial_cell-Vascular_Smooth_Muscle_Cell\|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group	ZFHX3 MEF2D	2.41e-03	173	19	2	901b8e6909c1f3849906fad9cee17b8f0bab050d
ToppCell	droplet-Lung-18m-Hematologic-myeloid-interstitial_macrophage\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TANC2 ZFHX3	2.44e-03	174	19	2	ca0c2f42544092848541863c4a47b334e6828b8a
ToppCell	10x5'-bone_marrow-Myeloid_Mac-Intermediate_macrophages\|bone_marrow / Manually curated celltypes from each tissue	PHLDA1 ZFHX3	2.44e-03	174	19	2	268abfc4d53a3ba3931dbcafffef09a72ea0edfa
ToppCell	droplet-Lung-18m-Hematologic-myeloid-interstitial_macrophage-interstitial_macrophage_l12\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	TANC2 ZFHX3	2.44e-03	174	19	2	33e5903adb746f693433bdca11a75c508bbf50c0
ToppCell	PBMC-Convalescent-Lymphocyte-B-B_cell-B_intermediate-B_intermediate-10\|Convalescent / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	MN1 MEF2A	2.44e-03	174	19	2	59ccc5a82507463e0a316ba6286cb25ec1a4091b
ToppCell	3'_v3-lymph-node_spleen-Hematopoietic_progenitors\|lymph-node_spleen / Manually curated celltypes from each tissue	MED12L MN1	2.44e-03	174	19	2	6d9bdf4d28ff8ebb66ffd1ccdd6a4fe9440a83f3
ToppCell	facs-Brain_Myeloid-Cerebellum-3m-Myeloid-microglial_cell\|Brain_Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MED12L MEF2A	2.46e-03	175	19	2	1ea6cf9da26601646f57fa14d558a5e9e1f0b345
ToppCell	facs\|World / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MN1 MEF2D	2.46e-03	175	19	2	53e96956019f984decc1c81376ebc88fbf3c4d40
ToppCell	facs-Skin-Anagen-24m-Epithelial-outer_bulge\|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PHLDA1 MN1	2.46e-03	175	19	2	5552ff1e13f931c8cd7780726c90b5609497a648
ToppCell	Fetal_29-31_weeks-Immune-dendritic_cell\|Fetal_29-31_weeks / Lineage, Cell type, age group and donor	SLC24A4 MED12L	2.52e-03	177	19	2	c5e829bc4594761666d65cace5a9c5d19c16f187
ToppCell	5'-Adult-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(C7+)\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PHLDA1 MN1	2.52e-03	177	19	2	bd602db857f37869ef76d14c05ef522c509f08ee
ToppCell	PBMC-Mild-cDC_11\|Mild / Compartment, Disease Groups and Clusters	SLC24A4 TANC2	2.52e-03	177	19	2	974305e4c0eff90134c4e58cf11b955d1eee0501
ToppCell	metastatic_Brain-T/NK_cells-Exhausted_Tfh\|T/NK_cells / Location, Cell class and cell subclass	ZFHX3 MEF2D	2.55e-03	178	19	2	9a3581a0158dfa5a1cc942f8c532afb5e38b272a
ToppCell	Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3\|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	SLC24A4 MED12L	2.55e-03	178	19	2	ccea3c8908d72f5fecd151a133048c8e9758304c
ToppCell	3'-GW_trimst-2-LargeIntestine-Mesenchymal-Pericytes-Immature_pericyte\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	PHLDA1 ZFHX3	2.55e-03	178	19	2	e5e4742e35c3d90f82b830d77bdbdc45828c7deb
ToppCell	droplet-Limb_Muscle-MUSCLE-30m\|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MEF2A SFPQ	2.55e-03	178	19	2	01dafd19de04eff459253eaa9a35debf8f3deedf
ToppCell	5'-GW_trimst-2-LymphNode-Mesenchymal-Pericytes-Contractile_pericyte_(PLN+)\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	ZFHX3 ALX4	2.63e-03	181	19	2	59527ad218e49386b04cabb97d53d2ed55a35961
ToppCell	Control-Lymphoid-B\|World / Disease state, Lineage and Cell class	TNRC6B KLHL14	2.63e-03	181	19	2	9124f1a610cfc3355ad87921cd3eb5346956475d
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage-lung_macrophage-Interstitial_macrophage_perivascular\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FOXJ2 MEF2D	2.66e-03	182	19	2	53213af34af3337f5edc734d3b7b79e4349eac0d
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage-lung_macrophage-Interstitial_macrophage_perivascular-Interstitial_macrophage_perivascular_L.1.2.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FOXJ2 MEF2D	2.66e-03	182	19	2	7909089ed6325c44edd6f9b7e8b1d542398222ea
ToppCell	droplet-Marrow-nan-3m-Myeloid-nan\|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	MEF2A KAT6A	2.66e-03	182	19	2	f8c73baaaca145e2efc48f10f636feb79c8fc779
ToppCell	Pericytes-Cryobiopsy_01\|World / lung cells shred on cell class, cell subclass, sample id	MN1 ZFHX3	2.66e-03	182	19	2	46c213597445b1f4f09dc367f27702d24b201daf
ToppCell	5'-Airway_Nasal-Immune_Myeloid-Myeloid_macrophage-lung_macrophage\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	FOXJ2 MEF2D	2.66e-03	182	19	2	4a85429d365c4b2d73fc921f261b4b7635ac40bd
ToppCell	10x3'2.3-week_12-13-Lymphocytic_B-B_lineage-immature_B_cell\|week_12-13 / cell types per 3 fetal stages;per 3',per 5'	TNRC6B KLHL14	2.66e-03	182	19	2	ab78df9de3878a6d67106a40094c893601de8076
ToppCell	wk_20-22-Mesenchymal-Chondrocyte-intermediate_chondrocyte\|wk_20-22 / Celltypes from embryonic and fetal-stage human lung	MN1 ZFHX3	2.69e-03	183	19	2	1464b5c4425e8776c4aeb4d2b560481d4bf13931
ToppCell	IPF-Lymphoid-B\|IPF / Disease state, Lineage and Cell class	TNRC6B KLHL14	2.69e-03	183	19	2	e37d2c015c34471a8a54a0299e94b0371e1ada5a
ToppCell	COVID-19-APC-like\|COVID-19 / group, cell type (main and fine annotations)	SLC24A4 MED12L	2.69e-03	183	19	2	b8f5afaf9ff1b2b1bc60be58654d1b23859dafa9
ToppCell	Control-APC-like-Dendritic_cells\|Control / group, cell type (main and fine annotations)	SLC24A4 MED12L	2.69e-03	183	19	2	8f9c8e2436f18ea7c265b08e4e149e19cb513a16
ToppCell	Control-APC-like\|Control / group, cell type (main and fine annotations)	SLC24A4 MED12L	2.69e-03	183	19	2	c313ac72cc9fa1583456d452393f61f0a4ca33a8
Drug	Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; PC3; HT_HG-U133A	TANC2 PHLDA1 TNRC6B SFPQ	1.25e-05	177	19	4	4652_DN
Drug	Tolbutamide [64-77-7]; Down 200; 14.8uM; PC3; HT_HG-U133A	MN1 PACS1 FBXO11 MEF2D	1.72e-05	192	19	4	3804_DN
Drug	Diethylstilbestrol [56-53-1]; Down 200; 15uM; PC3; HT_HG-U133A	PHLDA1 MN1 ZFHX3 MEF2D	1.83e-05	195	19	4	3812_DN
Drug	Fenbufen [36330-85-5]; Down 200; 15.8uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 FBXO11 KAT6A	1.90e-05	197	19	4	3618_DN
Drug	Nafcillin sodium salt monohydrate [7177-50-6]; Down 200; 8.8uM; PC3; HT_HG-U133A	TANC2 TNRC6B MN1 PACS1	1.90e-05	197	19	4	3983_DN
Drug	(1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A	PACS1 FBXO11 MEF2D KAT6A	1.94e-05	198	19	4	4367_DN
Drug	Dexamethasone acetate [1177-87-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A	TNRC6B PACS1 HELZ MEF2A	1.94e-05	198	19	4	6271_DN
Drug	Digoxigenin [1672-46-4]; Up 200; 10.2uM; MCF7; HT_HG-U133A	PHLDA1 SFPQ KAT6A	3.04e-04	160	19	3	5275_UP
Drug	Lanatoside C [17575-22-3]; Up 200; 4uM; MCF7; HT_HG-U133A	PHLDA1 SFPQ KAT6A	3.27e-04	164	19	3	3852_UP
Drug	Bisacodyl [603-50-9]; Up 200; 11uM; MCF7; HT_HG-U133A	MEF2D SFPQ KAT6A	3.69e-04	171	19	3	3297_UP
Drug	Methyl benzethonium chloride [25155-18-4]; Up 200; 8.6uM; MCF7; HT_HG-U133A	PHLDA1 MEF2D KAT6A	4.22e-04	179	19	3	6045_UP
Drug	Nortriptyline hydrochloride [894-71-3]; Up 200; 13.4uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 MEF2D	4.43e-04	182	19	3	7422_UP
Drug	Azacytidine-5 [320-67-2]; Up 200; 16.4uM; MCF7; HT_HG-U133A	PHLDA1 MEF2A SFPQ	4.65e-04	185	19	3	4128_UP
Drug	Cloperastine hydrochloride [14984-68-0]; Up 200; 11uM; PC3; HT_HG-U133A	PHLDA1 ZFHX3 MEF2D	4.72e-04	186	19	3	4271_UP
Drug	Nocodazole [31430-18-9]; Up 200; 13.2uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 KAT6A	4.72e-04	186	19	3	6793_UP
Drug	Ciclopirox ethanolamine [41621-49-2]; Down 200; 15uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 KAT6A	4.80e-04	187	19	3	5023_DN
Drug	Pregnenolone [145-13-1]; Up 200; 12.6uM; MCF7; HT_HG-U133A	TANC2 PHLDA1 MEF2D	4.80e-04	187	19	3	2856_UP
Drug	Mepenzolate bromide [76-90-4]; Up 200; 9.6uM; PC3; HT_HG-U133A	PHLDA1 ZFHX3 MEF2D	4.95e-04	189	19	3	4304_UP
Drug	Mepenzolate bromide [76-90-4]; Down 200; 9.6uM; PC3; HT_HG-U133A	TANC2 FBXO11 KAT6A	4.95e-04	189	19	3	4304_DN
Drug	Methotrexate [59-05-2]; Down 200; 8.8uM; PC3; HT_HG-U133A	PHLDA1 MN1 SFPQ	5.02e-04	190	19	3	6318_DN
Drug	Fenoprofen calcium salt dihydrate [53746-45-5]; Up 200; 7.2uM; PC3; HT_HG-U133A	PHLDA1 ZFHX3 MEF2D	5.02e-04	190	19	3	4274_UP
Drug	Oxyphenbutazone [129-20-4]; Up 200; 12.4uM; MCF7; HT_HG-U133A	PHLDA1 MEF2D KAT6A	5.02e-04	190	19	3	6844_UP
Drug	Phthalylsulfathiazole [85-73-4]; Down 200; 10uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 FBXO11	5.02e-04	190	19	3	5614_DN
Drug	Luteolin [491-70-3]; Down 200; 14uM; PC3; HT_HG-U133A	TANC2 MEF2A ZFHX3	5.10e-04	191	19	3	6658_DN
Drug	Leflunomide [75706-12-6]; Down 200; 14.8uM; MCF7; HT_HG-U133A	PHLDA1 MEF2D KAT6A	5.18e-04	192	19	3	6102_DN
Drug	17-AAG; Down 200; 1uM; PC3; HT_HG-U133A	PHLDA1 MN1 MEF2D	5.18e-04	192	19	3	4449_DN
Drug	AG-013608 [351320-38-2]; Down 200; 10uM; MCF7; HT_HG-U133A	TANC2 FBXO11 MEF2D	5.18e-04	192	19	3	6435_DN
Drug	Sulfamethoxazole [723-46-6]; Down 200; 15.8uM; MCF7; HT_HG-U133A	PHLDA1 TNRC6B KAT6A	5.26e-04	193	19	3	4690_DN
Drug	Zaprinast [37762-06-4]; Down 200; 14.8uM; PC3; HT_HG-U133A	TANC2 PHLDA1 PACS1	5.26e-04	193	19	3	6749_DN
Drug	Ethoxyquin [91-53-2]; Down 200; 18.4uM; PC3; HT_HG-U133A	TANC2 PACS1 FBXO11	5.26e-04	193	19	3	4321_DN
Drug	Zidovudine, AZT [30516-87-1]; Down 200; 15uM; PC3; HT_HG-U133A	PHLDA1 PACS1 ZFHX3	5.26e-04	193	19	3	6733_DN
Drug	(S)-(-)-Cycloserine [339-72-0]; Up 200; 39.2uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 KAT6A	5.26e-04	193	19	3	3870_UP
Drug	radicicol, diheterospora chlamydosporia; Down 200; 0.1uM; PC3; HT_HG-U133A	PHLDA1 PACS1 MEF2D	5.26e-04	193	19	3	4443_DN
Drug	Lynestrenol [52-76-6]; Down 200; 14uM; PC3; HT_HG-U133A	HELZ ZFHX3 SFPQ	5.34e-04	194	19	3	6756_DN
Drug	Dipyrone [5907-38-0]; Up 200; 12uM; PC3; HT_HG-U133A	PHLDA1 ZFHX3 MEF2D	5.34e-04	194	19	3	4310_UP
Drug	Rapamycin; Down 200; 0.1uM; MCF7; HT_HG-U133A	PACS1 FBXO11 MEF2A	5.34e-04	194	19	3	7001_DN
Drug	Chlortetracycline hydrochloride [64-72-2]; Down 200; 7.8uM; PC3; HT_HG-U133A	PHLDA1 HELZ ZFHX3	5.34e-04	194	19	3	6761_DN
Drug	Chloramphenicol [56-75-7]; Down 200; 12.4uM; PC3; HT_HG-U133A	ZFHX3 HTT KAT6A	5.34e-04	194	19	3	5047_DN
Drug	Proglumide [6620-60-6]; Down 200; 12uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 MEF2D	5.34e-04	194	19	3	3861_DN
Drug	Trichlormethiazide [133-67-5]; Down 200; 10.6uM; PC3; HT_HG-U133A	PHLDA1 PACS1 ZFHX3	5.42e-04	195	19	3	4198_DN
Drug	Naproxen [22204-53-1]; Up 200; 17.4uM; MCF7; HT_HG-U133A	TANC2 TNRC6B FBXO11	5.42e-04	195	19	3	1706_UP
Drug	Pivmecillinam hydrochloride [32887-03-9]; Down 200; 8.4uM; HL60; HT_HG-U133A	PHLDA1 MEF2D HTT	5.42e-04	195	19	3	2973_DN
Drug	genistein; Up 200; 10uM; MCF7; HT_HG-U133A	TANC2 PHLDA1 MEF2D	5.42e-04	195	19	3	1660_UP
Drug	Tiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Up 200; 6.4uM; PC3; HT_HG-U133A	PACS1 MEF2A ZFHX3	5.42e-04	195	19	3	2096_UP
Drug	PNU-0230031 [267429-39-0]; Down 200; 10uM; PC3; HT_HG-U133A	PHLDA1 PACS1 ZFHX3	5.42e-04	195	19	3	3732_DN
Drug	Pipenzolate bromide [125-51-9]; Down 200; 9.2uM; MCF7; HT_HG-U133A	TNRC6B PACS1 ZFHX3	5.42e-04	195	19	3	6821_DN
Drug	Isoetharine mesylate salt [7279-75-6]; Down 200; 12uM; MCF7; HT_HG-U133A	PHLDA1 ZFHX3 SFPQ	5.42e-04	195	19	3	3451_DN
Drug	Letrozole [112809-51-5]; Down 200; 14uM; HL60; HT_HG-U133A	PHLDA1 FBXO11 MEF2D	5.42e-04	195	19	3	2916_DN
Drug	Flutamide [13311-84-7]; Down 200; 14.4uM; HL60; HT_HG-U133A	TNRC6B FBXO11 MEF2A	5.42e-04	195	19	3	2358_DN
Drug	monastrol; Down 200; 100uM; MCF7; HG-U133A	PHLDA1 TNRC6B HTT	5.42e-04	195	19	3	681_DN
Drug	Corynanthine hydrochloride [66634-44-4]; Down 200; 10.2uM; PC3; HT_HG-U133A	PHLDA1 PACS1 ZFHX3	5.50e-04	196	19	3	4227_DN
Drug	(cis-) Nanophine [5072-45-7]; Up 200; 26.8uM; MCF7; HT_HG-U133A	MN1 PACS1 HTT	5.50e-04	196	19	3	3889_UP
Drug	Nalbuphine hydrochloride [23277-43-2]; Up 200; 10.2uM; PC3; HT_HG-U133A	PACS1 MEF2A KAT6A	5.50e-04	196	19	3	2063_UP
Drug	GSK-3 Inhibitor IX; Up 200; 0.5uM; PC3; HT_HG-U133A	TANC2 PACS1 HTT	5.50e-04	196	19	3	6559_UP
Drug	Fluocinonide [356-12-7]; Down 200; 8uM; PC3; HT_HG-U133A	PHLDA1 SFPQ KAT6A	5.50e-04	196	19	3	4314_DN
Drug	Prednisolone [50-24-8]; Down 200; 11uM; MCF7; HT_HG-U133A	PHLDA1 TNRC6B KAT6A	5.50e-04	196	19	3	7424_DN
Drug	Pantothenic acid calcium salt monohydrate [63409-48-3]; Down 200; 8uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 MEF2A	5.50e-04	196	19	3	4775_DN
Drug	N6-methyladenosine [1867-73-8]; Down 200; 14.2uM; PC3; HT_HG-U133A	MN1 PACS1 ZFHX3	5.58e-04	197	19	3	6732_DN
Drug	Triflupromazine hydrochloride [1098-60-8]; Up 200; 10.2uM; MCF7; HT_HG-U133A	TANC2 PACS1 FBXO11	5.58e-04	197	19	3	1691_UP
Drug	Ketoconazole [65277-42-1]; Down 200; 7.6uM; MCF7; HT_HG-U133A	FBXO11 ZFHX3 KAT6A	5.58e-04	197	19	3	5685_DN
Drug	Benzydamine hydrochloride [132-69-4]; Down 200; 11.6uM; PC3; HT_HG-U133A	TNRC6B HELZ KAT6A	5.58e-04	197	19	3	5811_DN
Drug	Phenazopyridine hydrochloride [136-40-3]; Down 200; 16uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 FBXO11	5.58e-04	197	19	3	6100_DN
Drug	Methocarbamol [532-03-6]; Up 200; 16.6uM; MCF7; HT_HG-U133A	PHLDA1 MN1 MEF2D	5.58e-04	197	19	3	2274_UP
Drug	Paroxetine maleate [64006-44-6]; Down 200; 1uM; PC3; HT_HG-U133A	PACS1 HELZ KAT6A	5.58e-04	197	19	3	4556_DN
Drug	Tyloxapol [25301-02-4]; Down 200; 4uM; MCF7; HT_HG-U133A	FBXO11 ZFHX3 HTT	5.58e-04	197	19	3	5672_DN
Drug	Brompheniramine maleate [980-71-2]; Up 200; 9.2uM; MCF7; HT_HG-U133A	PHLDA1 FBXO11 MEF2D	5.58e-04	197	19	3	4131_UP
Drug	Stachydrine hydrochloride; Up 200; 22.2uM; MCF7; HT_HG-U133A	FBXO11 MEF2D KAT6A	5.58e-04	197	19	3	2743_UP
Drug	Cefixime [79350-37-1]; Up 200; 8.8uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 KAT6A	5.58e-04	197	19	3	3247_UP
Drug	Propidium iodide [25535-16-4]; Down 200; 6uM; PC3; HT_HG-U133A	PACS1 ZFHX3 KAT6A	5.58e-04	197	19	3	5803_DN
Drug	Meclofenamic acid sodium salt monohydrate [6385-02-0]; Up 200; 11.8uM; MCF7; HT_HG-U133A	PHLDA1 MN1 KAT6A	5.58e-04	197	19	3	2291_UP
Drug	Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Down 200; 7.8uM; MCF7; HT_HG-U133A	FOXJ2 PHLDA1 TNRC6B	5.58e-04	197	19	3	2643_DN
Drug	Clenbuterol hydrochloride [21898-19-1]; Down 200; 12.8uM; MCF7; HT_HG-U133A	PHLDA1 ZFHX3 MEF2D	5.58e-04	197	19	3	3228_DN
Drug	Bisacodyl [603-50-9]; Down 200; 11uM; HL60; HT_HG-U133A	PHLDA1 TNRC6B MEF2D	5.58e-04	197	19	3	2435_DN
Drug	Iobenguane sulfate; Down 200; 10.8uM; PC3; HT_HG-U133A	MEF2A ZFHX3 HTT	5.66e-04	198	19	3	7299_DN
Drug	Pinacidil [85371-64-8]; Down 200; 16.4uM; MCF7; HT_HG-U133A	PHLDA1 FBXO11 HTT	5.66e-04	198	19	3	7437_DN
Drug	Carbarsone [121-59-5]; Down 200; 15.4uM; HL60; HT_HG-U133A	TNRC6B HTT KAT6A	5.66e-04	198	19	3	1313_DN
Drug	Carbimazole [22232-54-8]; Up 200; 21.4uM; MCF7; HT_HG-U133A	PHLDA1 FBXO11 MEF2D	5.66e-04	198	19	3	5399_UP
Drug	Ribostamycin sulfate salt [53797-35-6]; Up 200; 7.2uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 FBXO11	5.66e-04	198	19	3	6765_UP
Drug	ST021200; Down 200; 10uM; MCF7; HT_HG-U133A	PHLDA1 TNRC6B MEF2D	5.66e-04	198	19	3	7554_DN
Drug	(-)-Cinchonidine [485-71-2]; Down 200; 13.6uM; MCF7; HT_HG-U133A	TANC2 TNRC6B ZFHX3	5.66e-04	198	19	3	7190_DN
Drug	Ranitidine hydrochloride [66357-59-3]; Up 200; 11.4uM; PC3; HT_HG-U133A	TNRC6B PACS1 ZFHX3	5.66e-04	198	19	3	2088_UP
Drug	Dapsone [80-08-0]; Down 200; 16.2uM; HL60; HT_HG-U133A	PHLDA1 FBXO11 MEF2A	5.66e-04	198	19	3	1868_DN
Drug	Mefexamide hydrochloride [3413-64-7]; Down 200; 12.6uM; HL60; HG-U133A	TNRC6B FBXO11 MEF2A	5.66e-04	198	19	3	1438_DN
Drug	Mafenide hydrochloride [138-37-4]; Up 200; 18uM; PC3; HT_HG-U133A	PACS1 ZFHX3 MEF2D	5.66e-04	198	19	3	2124_UP
Drug	Norethynodrel [68-23-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A	FOXJ2 PHLDA1 KAT6A	5.75e-04	199	19	3	7471_DN
Drug	SC-58125; Down 200; 10uM; MCF7; HG-U133A	TANC2 MEF2D SFPQ	5.75e-04	199	19	3	254_DN
Drug	Captopril [62571-86-2]; Down 200; 17.2uM; MCF7; HT_HG-U133A	TANC2 PHLDA1 PACS1	5.75e-04	199	19	3	1488_DN
Drug	Sulfamerazine [127-79-7]; Down 200; 15.2uM; MCF7; HT_HG-U133A	PACS1 FBXO11 SFPQ	5.75e-04	199	19	3	6036_DN
Drug	Levodopa [59-92-7]; Up 200; 20.2uM; MCF7; HT_HG-U133A	PHLDA1 FBXO11 MEF2D	5.75e-04	199	19	3	1472_UP
Drug	Trimethobenzamide hydrochloride [554-92-7]; Down 200; 9.4uM; MCF7; HT_HG-U133A	TANC2 PACS1 ZFHX3	5.75e-04	199	19	3	1502_DN
Drug	2-Aminobenzenesulfonamide [3306-62-5]; Down 200; 23.2uM; PC3; HT_HG-U133A	MN1 PACS1 ZFHX3	5.75e-04	199	19	3	6321_DN
Drug	Thalidomide [50-35-1]; Up 200; 15.4uM; PC3; HT_HG-U133A	TNRC6B PACS1 ZFHX3	5.75e-04	199	19	3	2095_UP
Drug	Amiloride hydrochloride dihydrate [17440-83-4]; Down 200; 13.2uM; PC3; HG-U133A	PHLDA1 FBXO11 MEF2A	5.75e-04	199	19	3	1890_DN
Drug	Hydroxyzine dihydrochloride [2192-20-3]; Up 200; 9uM; MCF7; HT_HG-U133A	TANC2 PHLDA1 KAT6A	5.83e-04	200	19	3	1524_UP
Drug	Fenbendazole [43210-67-9]; Down 200; 13.4uM; PC3; HT_HG-U133A	MN1 PACS1 HELZ	5.83e-04	200	19	3	4542_DN
Drug	Nystatine [1400-61-9]; Down 200; 4.4uM; MCF7; HT_HG-U133A	PHLDA1 HELZ MEF2A	5.83e-04	200	19	3	4807_DN
Drug	Imipramine hydrochloride [113-52-0]; Up 200; 12.6uM; MCF7; HT_HG-U133A	PHLDA1 PACS1 FBXO11	5.83e-04	200	19	3	1685_UP
Drug	Benoxinate hydrochloride [5987-82-6]; Down 200; 11.6uM; MCF7; HT_HG-U133A	PHLDA1 MEF2A ZFHX3	5.83e-04	200	19	3	1476_DN
Drug	Loperamide hydrochloride [34552-83-5]; Down 200; 7.8uM; PC3; HT_HG-U133A	MN1 PACS1 MEF2D	5.83e-04	200	19	3	4672_DN
Drug	Diloxanide furoate [3736-81-0]; Down 200; 12.2uM; PC3; HT_HG-U133A	PACS1 FBXO11 MEF2D	5.83e-04	200	19	3	6679_DN
Disease	Abnormal corpus callosum morphology	MED12L MN1	5.88e-06	6	19	2	C1842581
Disease	Intellectual Disability	MED12L TANC2 MN1 PACS1 HTT	7.61e-06	447	19	5	C3714756
Disease	synophrys measurement	SLC24A4 ALX4 HTT	1.10e-05	68	19	3	EFO_0007906
Disease	Craniosynostosis	MN1 ALX4	7.41e-05	20	19	2	C0010278
Disease	attention deficit hyperactivity disorder (implicated_via_orthology)	MEF2A MEF2D	1.47e-04	28	19	2	DOID:1094 (implicated_via_orthology)
Disease	lung adenocarcinoma (is_implicated_in)	ZFHX3 ALX4	4.54e-04	49	19	2	DOID:3910 (is_implicated_in)
Disease	neutrophil percentage of leukocytes	FOXJ2 TNRC6B HELZ HTT	5.48e-04	610	19	4	EFO_0007990
Disease	diastolic blood pressure, systolic blood pressure	TNRC6B RBM33 FBXO11 ZFHX3	7.78e-04	670	19	4	EFO_0006335, EFO_0006336
Disease	word reading	SLC24A4 ZFHX3	7.98e-04	65	19	2	EFO_0005300
Disease	hepatocellular carcinoma (is_marker_for)	FBXO11 ZFHX3 ALX4	9.02e-04	301	19	3	DOID:684 (is_marker_for)
Disease	intellectual disability (implicated_via_orthology)	MEF2A MEF2D	1.06e-03	75	19	2	DOID:1059 (implicated_via_orthology)
Disease	risk-taking behaviour	SLC24A4 FBXO11 ZFHX3 HTT	1.27e-03	764	19	4	EFO_0008579
Disease	aspartate aminotransferase measurement, serum alanine aminotransferase measurement, low density lipoprotein triglyceride measurement, body fat percentage, high density lipoprotein cholesterol measurement, sex hormone-binding globulin measurement	PACS1 ZFHX3 HTT	1.56e-03	364	19	3	EFO_0004612, EFO_0004696, EFO_0004735, EFO_0004736, EFO_0007800, EFO_0009946
Disease	Neurodevelopmental Disorders	TANC2 TNRC6B	1.62e-03	93	19	2	C1535926
Disease	upper face morphology measurement	SLC24A4 ALX4	1.76e-03	97	19	2	EFO_0010949
Disease	lymphocyte count	MED12L TNRC6B HELZ HTT KLHL14	1.94e-03	1464	19	5	EFO_0004587
Disease	bitter alcoholic beverage consumption measurement	TNRC6B ZFHX3	3.28e-03	133	19	2	EFO_0010092
Disease	lung non-small cell carcinoma (is_implicated_in)	FBXO11 ZFHX3	3.57e-03	139	19	2	DOID:3908 (is_implicated_in)
Disease	body fat percentage	PACS1 ZFHX3 HTT	3.58e-03	488	19	3	EFO_0007800
Disease	breast carcinoma	TNRC6B MN1 ALX4 KLHL14	3.62e-03	1019	19	4	EFO_0000305
Disease	peak expiratory flow	MN1 PACS1 ALX4	3.79e-03	498	19	3	EFO_0009718

Protein segments in the cluster

Peptide	Gene	Start	Entry
PPPQPQPQQQQPQPQ	ALX4	101	Q9H161
QPQQQQPQPQPPAQP	ALX4	106	Q9H161
DPQQNQEQQPPPQPP	SLC24A4	386	Q8NFF2
QPQPQQPQQQPPPQH	RBM33	591	Q96EV2
QPQQQPPPQHQPPHQ	RBM33	596	Q96EV2
QQPQQPQPQQPPQPQ	MED12L	2066	Q86YW9
PPPQQQQQQQQPPQP	FOXJ2	296	Q9P0K8
QQQQQPPPPPQPQPQ	MEF2A	426	Q02078
QPQPQPPQPQPRQEM	MEF2A	436	Q02078
NLPEQPNQIPPQPNQ	HELZ	1386	P42694
QPPPQQQQQQPPQQP	PACS1	31	Q6VY07
NQQQQPPPPPPQQPQ	KAT6A	1646	Q92794
QPPPPQQQPQQQPQP	KAT6A	1671	Q92794
QQQQQQQQPPPPPPP	HTT	31	P42858
QPSQQQQPPPQEEPG	KLHL14	91	Q9P2G3
QQQQQQPPQQPPPQP	FBXO11	21	Q86XK2
PQQQPPPPPQQQQQQ	FBXO11	41	Q86XK2
QPQQPQQPQQPQPPQ	MEF2D	366	Q14814
QQPQQPQPPQQQPPQ	MEF2D	371	Q14814
PQPPQQQPPQPQQPQ	MEF2D	376	Q14814
QQPPQPQQPQPQQPQ	MEF2D	381	Q14814
PQQPQPQQPQQPQQP	MEF2D	386	Q14814
PQQAPPPPQQQPPQQ	MN1	341	Q10571
PPPQQQPPQQPPQQQ	MN1	346	Q10571
QQPQQPPPPPQPQQQ	TANC2	1376	Q9HCD6
HQQQQQPPPQQPPPQ	SFPQ	66	P23246
PQPHQQQQPPPPPQD	SFPQ	91	P23246
QLQPQPQPQPQPQPQ	PHLDA1	316	Q8WV24
QQQQPPQQPPPPQPE	TNRC6B	821	Q9UPQ9
QQQQPQVQQPPPPPA	ZFHX3	3201	Q15911